ALX Oncology Holdings (ALXO) Skyrockets +25% in April: A Deeper Dive into Earnings Results

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALXO's RSI Oscillator exited the oversold zone, 34 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.

Following a +11.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 212 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALXO as a result. In 75 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. ALXO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-1.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.